-0.09%
5.96%
22.46%
34.17%
39.95%
-5.56%
52.51%
AI Spotlight on EUZ
Create a Free
Company Description
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide.It operates in two segments, Medical and Isotope Products.The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma.
This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants.The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring.This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products.
The company was founded in 1992 and is headquartered in Berlin, Germany.
Market Data
| Last Price | 57.8 |
| Change Percentage | -0.09% |
| Open | 56.35 |
| Previous Close | 57.85 |
| Market Cap ( Millions) | 1205 |
| Volume | 78897 |
| Year High | 62.05 |
| Year Low | 32.74 |
| M A 50 | 52.3 |
| M A 200 | 45.62 |
Financial Ratios
| FCF Yield | 3.64% |
| Dividend Yield | 0.95% |
| ROE | 12.31% |
| Debt / Equity | 20.90% |
| Net Debt / EBIDTA | -64.72% |
| Price To Book | 4.85 |
| Price Earnings Ratio | 41.07 |
| Price To FCF | 27.47 |
| Price To sales | 4.34 |
| EV / EBITDA | 16.41 |
News
- Feb -18 - Private equity firms own 32% of Eckert & Ziegler SE (ETR:EUZ) shares but individual investors control 40% of the company
- Feb -04 - Undiscovered Gems Three Promising Small Caps To Consider
- Jan -23 - Why Eckert & Ziegler SE (ETR:EUZ) Could Be Worth Watching
- Jan -06 - Undiscovered Gems To Explore In January 2025
- Jan -03 - Is Eckert & Ziegler SE's (ETR:EUZ) Latest Stock Performance Being Led By Its Strong Fundamentals?
- Nov -22 - Uncover These 3 Undiscovered Gems with Promising Potential
- Oct -21 - Three Undiscovered Gems in Germany to Enhance Your Portfolio
- Oct -18 - Discovering Germany's Undiscovered Gems This October 2024
- Oct -15 - Undiscovered Gems in Germany Three Stocks to Watch in October 2024
- Oct -03 - Three Hidden German Stocks Backed By Strong Fundamentals
- Oct -01 - Energiekontor And 2 Other Undiscovered Gems In Germany
- Sep -30 - Three Undiscovered Gems In Germany To Consider For Your Portfolio
- Sep -27 - Discovering Eckert & Ziegler And 2 Other Hidden Small Cap Treasures
- Sep -26 - Uncovering Eckert & Ziegler And 2 Other Hidden German Small Cap Gems
- Sep -25 - Discovering Germany's Undiscovered Gems for September 2024
- Sep -24 - Undiscovered Gems in Germany to Watch This September 2024
- Sep -23 - Undiscovered Gems in Germany To Watch This September 2024
- Sep -20 - Discovering 3 Hidden German Small Caps with Strong Potential
- Sep -12 - The past three years for Eckert & Ziegler (ETR:EUZ) investors has not been profitable
- Aug -29 - Undiscovered Gems Südwestdeutsche Salzwerke Plus 2 Small Caps with Strong Fundamentals
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Isotope Products
Expected Growth : 7 %
What the company do ?
Isotope Products from Eckert & Ziegler Strahlen- und Medizintechnik AG provide radioactive isotopes for medical, industrial, and research applications, offering a range of products for diagnostics, therapy, and sterilization.
Why we expect these perspectives ?
Eckert & Ziegler's Isotope Products segment growth is driven by increasing demand for nuclear medicine and radioisotope applications, expansion into emerging markets, strategic partnerships, and investments in research and development to enhance product offerings and improve manufacturing efficiency.
Segment n°2 -> Medical
Expected Growth : 9 %
What the company do ?
Eckert & Ziegler Strahlen- und Medizintechnik AG's Medical segment provides radiopharmaceuticals and radioisotope technology for cancer treatment and diagnostics.
Why we expect these perspectives ?
Eckert & Ziegler's 9% growth in Medical segment is driven by increasing demand for radiopharmaceuticals, expansion in emerging markets, and strategic acquisitions. Growing need for cancer treatment and diagnostic imaging also contribute to growth. Additionally, the company's focus on research and development of new products and technologies enhances its market position.
Eckert & Ziegler Strahlen- Und Medizintechnik Ag Products
| Product Range | What is it ? |
|---|---|
| Radiopharmaceuticals | Eckert & Ziegler develops and manufactures radiopharmaceuticals for diagnostic and therapeutic applications, including cancer treatment and imaging. |
| Radioisotope Generators | Eckert & Ziegler designs and manufactures radioisotope generators for the production of short-lived radioisotopes, used in medical research and diagnostics. |
| Radiation Detection and Measurement | Eckert & Ziegler offers a range of radiation detection and measurement instruments for industrial, medical, and research applications. |
| Medical Imaging | Eckert & Ziegler provides medical imaging solutions, including SPECT and PET cameras, for diagnostic imaging in hospitals and research institutions. |
| Cancer Treatment | Eckert & Ziegler develops and manufactures cancer treatment solutions, including brachytherapy and external beam therapy. |
| Radiation Therapy | Eckert & Ziegler provides radiation therapy solutions, including external beam therapy and brachytherapy, for cancer treatment. |
Eckert & Ziegler Strahlen- und Medizintechnik AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for Eckert & Ziegler Strahlen- und Medizintechnik AG is moderate, as there are alternative products and services available in the market, but they are not highly substitutable.
Bargaining Power Of Customers
The bargaining power of customers for Eckert & Ziegler Strahlen- und Medizintechnik AG is low, as the company operates in a niche market with limited customer base, and customers have limited bargaining power.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Eckert & Ziegler Strahlen- und Medizintechnik AG is moderate, as the company relies on a few key suppliers for its raw materials, but has some bargaining power due to its size and reputation.
Threat Of New Entrants
The threat of new entrants for Eckert & Ziegler Strahlen- und Medizintechnik AG is low, as the company operates in a highly regulated industry with high barriers to entry, and new entrants would face significant challenges in entering the market.
Intensity Of Rivalry
The intensity of rivalry for Eckert & Ziegler Strahlen- und Medizintechnik AG is high, as the company operates in a highly competitive market with several established players, and the company needs to continuously innovate and differentiate itself to maintain its market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 20.22% |
| Debt Cost | 9.41% |
| Equity Weight | 79.78% |
| Equity Cost | 9.41% |
| WACC | 9.41% |
| Leverage | 25.34% |
Eckert & Ziegler Strahlen- und Medizintechnik AG : Quality Control
Eckert & Ziegler Strahlen- und Medizintechnik AG passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| INMD | InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and … |
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| CHEMM.CO | ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in … |
| GBT.PA | Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and … |
| XVIVO.ST | Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
InMode
A-Score
1-Year Total Return ->
🥈
Xvivo Perfusion
A-Score
1-Year Total Return ->
🥉
ChemoMetec
A-Score
1-Year Total Return ->
4
Eckert & Ziegler
A-Score
1-Year Total Return ->
5
Guerbet
A-Score
1-Year Total Return ->
6
